AstraZenecom's $1 billion inhaler emergency?

November 4, CDE official website shows that Sichuan Hai Mengzhisen Biotech| Shenyang Xingqi eye drug sulfuric acid Tebutalin atomization inhalation with solution imitation 4 categories of listing applications were accepted. In recent years, china's public medical institutions terminal Tebtalin inhaler sales of more than 1 billion yuan, sales in the first half of this year more than 400 million yuan, the production of only AstraZeneta. In April this year, Sichuan Meida Kanghuakang Pharmaceuticals' sulfate tebutalin atomization inhalation solution was first approved. Prior to this, Shijiazhuang four drugs, health Yuanhai Pharmaceuticals | Health Yuan Pharmaceutical Group and other 6 enterprises submitted imitation 4 categories of listing applications in the review and approval (in the drug review center).In recent years, china's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal Tebutalin inhaler sales exceeded 1 billion yuan, in 2019 a new high, up 4.99 percent year-on-year;In April this year, Sichuan Meida Kanghuakang Pharmaceuticals' sulfate tebutalin atomization inhalation solution was first approved. Prior to this, Shijiazhuang four drugs, four Trump Reiter pharmaceutical industry, health yuan seaside pharmaceutical | health yuan pharmaceutical group and other 6 enterprises submitted imitation 4 categories of listing applications in the review and approval (in the drug review center). (Mi net)